Repository logo
 

Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Tchasovnikarova, IA 
Timms, RT 
Douse, CH 
Roberts, RC 

Abstract

Dominant mutations in the MORC2 gene have recently been shown to cause axonal Charcot–Marie–Tooth (CMT) disease, but the cellular function of MORC2 is poorly understood. Here, through a genome-wide CRISPR–Cas9-mediated forward genetic screen, we identified MORC2 as an essential gene required for epigenetic silencing by the HUSH complex. HUSH recruits MORC2 to target sites in heterochromatin. We exploited a new method, differential viral accessibility (DIVA), to show that loss of MORC2 results in chromatin decompaction at these target loci, which is concomitant with a loss of H3K9me3 deposition and transcriptional derepression. The ATPase activity of MORC2 is critical for HUSH-mediated silencing, and the most common alteration affecting the ATPase domain in CMT patients (p.Arg252Trp) hyperactivates HUSH-mediated repression in neuronal cells. These data define a critical role for MORC2 in epigenetic silencing by the HUSH complex and provide a mechanistic basis underpinning the role of MORC2 mutations in CMT disease.

Description

Keywords

Adenosine Triphosphatases, CRISPR-Cas Systems, Charcot-Marie-Tooth Disease, Chromatin Assembly and Disassembly, Epigenetic Repression, Gene Silencing, HeLa Cells, Heterochromatin, Histone Code, Histone-Lysine N-Methyltransferase, Histones, Humans, Lysine, Methylation, Multiprotein Complexes, Mutation, Missense, Neurons, Protein Domains, Protein Interaction Mapping, Protein Methyltransferases, Protein Processing, Post-Translational, Transcription Factors, Transgenes

Journal Title

Nature Genetics

Conference Name

Journal ISSN

1061-4036
1546-1718

Volume Title

49

Publisher

Nature Publishing Group
Sponsorship
Wellcome Trust (101908/Z/13/Z)
Biotechnology and Biological Sciences Research Council (BB/N011791/1)
Wellcome Trust (101835/Z/13/Z)
Wellcome Trust (201387/Z/16/Z)
This work was supported by the Wellcome Trust, through a Principal Research Fellowship to P.J.L. (101835/Z/13/Z), a Senior Research Fellowship to Y.M. (101908/Z/13/Z), a Sir Henry Wellcome Postdoctoral Fellowship to R.T.T. (201387/Z/16/Z) and a PhD studentship to I.A.T., and by the BBSRC, through a Future Leader Fellowship to C.H.D. I.A.T. is supported as a Damon Runyon Fellow by the Damon Runyon Cancer Research Foundation (DRG-2277-16). The CIMR is in receipt of a Wellcome Trust strategic award.